Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) is 28.98% higher on its value in year-to-date trading and has touched a low of $12.54 and a high of $28.91 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCYC stock was last observed hovering at around $23.73 in the last trading session, with the day’s loss setting it -0.41%.
Currently trading at $23.32, the stock is -5.58% and 5.25% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.63 million and changing -1.73% at the moment leaves the stock 13.40% off its SMA200. BCYC registered 9.64% gain for a year compared to 6-month gain of 17.01%. The firm has a 50-day simple moving average (SMA 50) of $15.45 and a 200-day simple moving average (SMA200) of -$2.46.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.58% loss in the last 1 month and extending the period to 3 months gives it a 26.46%, and is -4.93% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.13% over the week and 5.70% over the month.
Bicycle Therapeutics Plc ADR (BCYC) has around 284 employees, a market worth around $989.47M and $27.07M in sales. Profit margin for the company is -669.66%. Distance from 52-week low is 85.96% and -19.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.11%).
Bicycle Therapeutics Plc ADR quarterly earnings per share for the current quarter are estimated at -$1.24 with sales reaching $6.03M over the same period.The EPS is expected to shrink by -1.53% this year, but quarterly earnings will post 1.90% year-over-year. Quarterly sales are estimated to grow 23.20% in year-over-year returns.
137 institutions hold shares in Bicycle Therapeutics Plc ADR (BCYC), with institutional investors hold 98.07% of the company’s shares. The shares outstanding are 42.43M, and float is at 41.93M with Short Float at 6.09%. Institutions hold 91.99% of the Float.
The top institutional shareholder in the company is Deep Track Capital, Lp with over 2.82 million shares valued at $71.94 million. The investor’s holdings represent 13.23% of the BCYC Shares outstanding. As of Jun 29, 2023, the second largest holder is Paradigm Biocapital Advisors LP with 1.99 million shares valued at $50.67 million to account for 9.32% of the shares outstanding. The other top investors are Jefferies Financial Group Inc. which holds 1.95 million shares representing 9.14% and valued at over $49.71 million, while First Light Asset Management, LLC holds 8.16% of the shares totaling 1.74 million with a market value of $44.39 million.
Bicycle Therapeutics Plc ADR (BCYC) Insider Activity
The most recent transaction is an insider sale by Lee Kevin, the company’s Chief Executive Officer. SEC filings show that Lee Kevin sold 8,703 shares of the company’s common stock on Jan 03 ’24 at a price of $17.50 per share for a total of $0.15 million. Following the sale, the insider now owns 0.39 million shares.
Bicycle Therapeutics Plc ADR disclosed in a document filed with the SEC on Jan 03 ’24 that Crockett Nigel (Chief Business Officer) sold a total of 2,643 shares of the company’s common stock. The trade occurred on Jan 03 ’24 and was made at $17.50 per share for $46252.0. Following the transaction, the insider now directly holds 48716.0 shares of the BCYC stock.
Still, SEC filings show that on Jan 03 ’24, Skynner Michael (Chief Technology Officer) disposed off 2,643 shares at an average price of $17.50 for $46252.0. The insider now directly holds 95,839 shares of Bicycle Therapeutics Plc ADR (BCYC).
